With the exponential increase of interest in dry eye or ocular surface disease (OSD) among physicians and the industry, we are fortunate to have access to exciting new diagnostic and imaging technology as well as new treatment options and therapeutics for some of our most frustrated patients.
Shire plc obtained U.S. Food and Drug Administration (FDA) approval for Xiidra (lifitegrast ophthalmic solution) 5%, a twice-daily eye drop indicated for the treatment of the signs and symptoms of dry eye disease in adult patients.
Certainly, one would assume that nothing could be safer than a product designed for use with children. Television commercials with smiling, happy babies covered in frothy bubbles imply the product is harmless. Ubiquitous marketing alone creates a subconscious sense of safety for both doctor and patient.
Dry eye disease is one of the most common conditions encountered by eye care professionals, yet measurement of tear volume remains difficult. A newly developed tool is reliable and straightforward to use.
Dry eye represents a major opportunity with more than 25 million people suffering from the condition in the U.S.,1 and meibomian gland dysfunction (MGD) is thought to be the most common cause of dry eye.2 During a session at SECO, Walt Whitley, OD, MBA, FAAO, shared his tips for making the most of this opportunity in your practice.
First acquired during birth from the mother and rapidly thereafter from the surrounding environment, bacteria colonize our conjunctiva and lacrimal systems. It is estimated that more than 200 species of bacteria commonly inhabit the human conjunctival mucosa.
Dry eye disease (DED) has long been thought to be a progressive condition, but a study published in Ophthalmology found that most of its participants who were diagnosed with DED reported no change or some level of improvement.
A common barrier to many practitioners is the concern that their practice does not have the patient foundation to make investment in the services economically profitable. I assure you that OSD management will profit the patient in many ways that includes clearer, more comfortable vision, enhancing their productivity and overall wellbeing.